Estrogen News and Research

Latest Estrogen News and Research

Bone drug effective in improving breast cancer survival

In a chance finding a bone drug was found to be effective in breast cancer. While doctors were prescribing young women a medicine to keep their bones strong during breast cancer treatment they noted that after seven years it did more than that - the bone drug improved survival, as much as most chemotherapy could do.

12 Dec 2011

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.

12 Dec 2011

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes & Control.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Breast cancer risks and management updates

A new report that looks at the environmental factors that affect risk of breast cancer is out. It suggests that women can reduce their risk by avoiding unnecessary medical radiation, forgoing hormone treatments for menopause that combine estrogen and progestin, limiting alcohol intake and minimizing weight gain.

8 Dec 2011

Heart patients may experience fewer traumas with new invention

Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.

8 Dec 2011

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

8 Dec 2011

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.

8 Dec 2011

Notch inhibitor appears to treat breast cancer

In a novel therapeutic approach to treating breast cancer, Loyola University Medical Center researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells.

8 Dec 2011

Combination treatment extends lives of women with metastatic breast cancer

Changing the order in which two drugs are taken significantly extended the lives of women with metastatic breast cancer, a study has found.

8 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

AmLactin can help the skin through menopause

Womanhood definitely has its advantages—studies even show we live longer than men—but menopause isn't on the list of perks. Sometime between the ages of 40-58, our bodies will inevitably experience a drop in estrogen production and begin a metamorphosis.

7 Dec 2011

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.

2 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Alzheimer's disease affects women more than men

Many women suffer memory loss and/or confusion at some point in their lives, but as many as 5 million Americans suffer from a much more serious disease, Alzheimer's. According to statistics from the National Institute on Aging, Alzheimer's disease is the most common form of dementia in older people. Alzheimer's is a progressive brain disease; it is irreversible and causes a decline in memory and cognitive skills.

1 Dec 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Herbicide atrazine linked to reproductive dysfunction

An international team of researchers has reviewed the evidence linking exposure to atrazine - an herbicide widely used in the U.S. and more than 60 other nations - to reproductive problems in animals. The team found consistent patterns of reproductive dysfunction in amphibians, fish, reptiles and mammals exposed to the chemical.

29 Nov 2011

Estrogen News and Research

Latest Estrogen News and Research

Bone drug effective in improving breast cancer survival

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Many postmenopausal women quit breast cancer drugs early because of side effects

MRI can predict breast cancer prognosis

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Breast cancer risks and management updates

Heart patients may experience fewer traumas with new invention

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Notch inhibitor appears to treat breast cancer

Combination treatment extends lives of women with metastatic breast cancer

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

AmLactin can help the skin through menopause

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Alzheimer's disease affects women more than men

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Herbicide atrazine linked to reproductive dysfunction

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Estrogen News and Research

Latest Estrogen News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in